Murray R J, Wang D, Young L S, Wang F, Rowe M, Kieff E, Rickinson A B
Department of Cancer Studies, University of Birmingham, United Kingdom.
J Virol. 1988 Oct;62(10):3747-55. doi: 10.1128/JVI.62.10.3747-3755.1988.
Cytotoxic T cells from Epstein-Barr virus (EBV)-immune individuals specifically kill EBV-transformed B cells from HLA class I antigen-matched donors even though the latently infected cells express only a restricted set of virus genes. The virus-induced target antigens recognized by these immune T cells have not been identified. In our experiments, EBV DNA sequences encoding the virus latent gene products Epstein-Barr nuclear antigen (EBNA)1, EBNA 2, and EBNA-LP and the latent membrane protein (LMP) were individually expressed in a virus-negative human B-lymphoma cell line, Louckes. Transfected clones expressing LMP were killed by EBV-specific cytotoxic T-cell preparations from each of three virus-immune donors HLA matched with Louckes through HLA-A2, B44 antigens; control transfectants or clones expressing one of the EBNA proteins were not recognized. Expression of LMP in a second virus-negative B-cell line, BL41, sensitized these cells to EBV-specific cytolysis restricted through the HLA-A11 antigen. To distinguish between the viral protein and an induced human B-cell activation antigen as the target for T-cell recognition, LMP was then expressed in a murine mastocytoma cell line, P815-A11-restricted human T cells. The LMP-expressing P815-A11 transfectants were susceptible to lysis by EBV-specific cytotoxic T cells from three HLA-A11-positive individuals. Both Louckes and P815-A11 cells were also transfected with constructs capable of encoding a truncated form of LMP (Tr-LMP) which lacks the N-terminal 128 amino acids of the full-length protein. Tr-LMP-expressing transfectants were not recognized by the above T-cell preparations. The results suggest that LMP, and, in particular, epitopes derived from the N-terminal region of the protein, provides one of the target antigens for the EBV-induced human cytotoxic T-cell response.
来自爱泼斯坦-巴尔病毒(EBV)免疫个体的细胞毒性T细胞能够特异性杀伤来自HLA I类抗原匹配供体的EBV转化B细胞,即便这些潜伏感染细胞仅表达一组有限的病毒基因。这些免疫T细胞识别的病毒诱导靶抗原尚未得到鉴定。在我们的实验中,编码病毒潜伏基因产物爱泼斯坦-巴尔核抗原(EBNA)1、EBNA 2和EBNA-LP以及潜伏膜蛋白(LMP)的EBV DNA序列分别在一种病毒阴性的人B淋巴瘤细胞系Louckes中表达。表达LMP的转染克隆被来自与Louckes通过HLA-A2、B44抗原进行HLA匹配的三名病毒免疫供体的EBV特异性细胞毒性T细胞制剂所杀伤;表达EBNA蛋白之一的对照转染体或克隆未被识别。LMP在第二种病毒阴性B细胞系BL41中的表达使这些细胞对通过HLA-A11抗原限制的EBV特异性细胞溶解敏感。为了区分病毒蛋白和诱导性人B细胞活化抗原作为T细胞识别的靶标,随后在鼠肥大细胞瘤细胞系P815-A11限制的人T细胞中表达LMP。表达LMP的P815-A11转染体易被来自三名HLA-A11阳性个体的EBV特异性细胞毒性T细胞裂解。Louckes和P815-A11细胞也用能够编码全长蛋白N端128个氨基酸缺失的截短形式LMP(Tr-LMP)的构建体进行转染。表达Tr-LMP的转染体未被上述T细胞制剂识别。结果表明,LMP,尤其是源自该蛋白N端区域的表位,是EBV诱导的人细胞毒性T细胞反应的靶抗原之一。